Pharmacogenomics in Pulmonary Arterial Hypertension
|ClinicalTrials.gov Identifier: NCT00593905|
Recruitment Status : Unknown
Verified January 2012 by Raymond Benza, West Penn Allegheny Health System.
Recruitment status was: Recruiting
First Posted : January 15, 2008
Last Update Posted : January 24, 2012
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key disease-specific and therapy specific genes. Also characterized is the relationship between these polymorphisms and the severity of Pulmonary Arterial Hypertension using either baseline hemodynamic or clinical surrogates for disease severity.
Hypothesis: Polymorphisms influence the efficacy and toxicity of specific Pulmonary Arterial Hypertension therapy as well as development/severity of PAH via their effect on PA remodeling, drug response, or metabolism.
This study requires a one time 8.5 ml blood sample and clinical data to be obtained at initiation of therapy, 4 months after initiation of therapy and 12 months after initiation of therapy.
|Condition or disease||Intervention/treatment|
|Pulmonary Arterial Hypertension Pulmonary Hypertension PAH WHO Group I||Drug: Sitaxsentan Drug: Bosentan, Ambrisentan|
This study will make use of a large population of well defined patients with Pulmonary Arterial Hypertension who were enrolled in Encysive Pharmaceutical's STRIDE clinical trials or who have received bosentan or ambrisentan for 4 months or longer. This international study constitutes the largest clinical study of this deadly disease and in such has great potential to alter the clinical practice by revealing novel gene-drug interactions. This study tests the hypothesis by executing the following aims:
Aim 1: Determine in Pulmonary Arterial Hypertension (the relationship between known disease-specific polymorphisms (Serotonin transporter gene and PAI HindIII) and variants in BMPR2 and SMAD4 with several well-defined clinical efficacy endpoints of sitaxsentan, bosentan, and ambrisentan therapy.
Aim 2: Determine in Pulmonary Arterial Hypertension the relationship between existing potentially "therapy-specific" polymorphisms in the ET-1, ETAR, ETBR, NPR-C, prostacyclin receptor and prostacyclin synthase with several well-defined clinical efficacy endpoints of sitaxsentan, bosentan, and ambrisentan therapy.
Aim 3: Characterize the relationship between any treatment effect, these polymorphisms and PAH severity, using either clinical data or clinical surrogates for disease activity.
***This study was funded by the NIH from 2005 - 2009. In August 2009 a no-cost extension was granted and this study continued until the end of July 2010. Currently the study is still active and does still have several active sites participating; however, the study is funded by the internal institution and there is no contributing federal funding.***
|Study Type :||Observational|
|Estimated Enrollment :||1300 participants|
|Official Title:||Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes|
|Study Start Date :||July 2005|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2013|
Sitaxsentan sodium 100 mg tablet every morning
Other Name: Sitaxsentan-Thelin
Drug: Bosentan, Ambrisentan
Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
- 6 Minute Walk Test [ Time Frame: 12 months after initiation of drug therapy ]
- Hemodynamics - Right Heart Catheterization [ Time Frame: 12 months after intitation of drug therapy ]
- Borg [ Time Frame: 12 months after initiation of drug therapy ]
- Functional Class - FC [ Time Frame: 12 months after intitation of drug therapy ]
- Toxicities [ Time Frame: 12 months after initiation of drug therapy ]
- Time of Clinical Worsening [ Time Frame: 12 months after initiation of drug therapy ]
- Decline in WHO Functional Class [ Time Frame: 12 months after initiation of drug therapy ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00593905
|Contact: Andrea L Nowicki, BAfirstname.lastname@example.org|
|Contact: Raymond L Benza, MDemail@example.com|
|United States, Pennsylvania|
|Allegheny General Hospital||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15212|
|Contact: Andrea L Nowicki, BA 412-359-3653 firstname.lastname@example.org|
|Contact: Raymond L Benza, MD 412.359.3584 email@example.com|
|Principal Investigator: Raymond L Benza, MD|
|Principal Investigator:||Raymond L Benza, MD||Allegheny General Hospital/Allegheny-Singer Research Institute of West Penn Allegheny Health System|